Source: European Medicines Agency (EU) Revision Year: 2025 Publisher: Rare Thyroid Therapeutics International AB, Klara Norra Kyrkogata 26, 111 22, Stockholm, Sweden
Emcitate 350 microgram dispersible tablets.
| Pharmaceutical Form |
|---|
|
Dispersible tablet. White, oblong tablet (size: 10 mm long, 5 mm wide) with score lines on both sides. The tablet can be divided into equal doses. |
Each tablet contains 350 micrograms tiratricol.
Excipient with known effect:
Each tablet contains 19 mg of lactose (corresponding to 20 mg of lactose monohydrate).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Tiratricol |
Tiratricol (3,3',5-triiodothyroacetic acid) is a naturally circulating metabolite of active thyroid hormone (T3) with a high degree of structural similarity and follows the same downward degradation pathway (deiodination and conjugation) and elimination via bile and urine. Tiratricol has been demonstrated to be able to enter MCT8 dependent cells without a functioning MCT8 transporter unlike T3 and T4. Tiratricol can thereby replace T3 in MCT8 dependent tissues and restore normal thyroid hormone activity across tissues. |
| List of Excipients |
|---|
|
Lactose monohydrate |
PVC/Aluminium blister.
Pack size of 60 dispersible tablets.
Rare Thyroid Therapeutics International AB, Klara Norra Kyrkogata 26, 111 22, Stockholm, Sweden
EU/1/24/1897/001
| Drug | Countries | |
|---|---|---|
| EMCITATE | Estonia, Lithuania |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.